ClinicalTrials.gg
CompletedNCT04165096Updated Jun 26, 2026Results posted

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

A Phase 2 interventional study of Pembrolizumab and Boserolimab in Carcinoma, Non-Small-Cell Lung, sponsored by Merck Sharp & Dohme LLC. Completed at 39 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc — 14 open to participants now, 26 under way, 18 of them phase 3. Carcinoma, Non-Small-Cell Lung · Merck & Co., Inc.

Enrollment
46th of 88
128 · median 149
Started
2020
with 1 other
Phase 2
24 of 91
2 open now
Registered
58th of 91
by date

Among the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, this one is the 46th largest by enrollment of the 88 interventional ones that give a count, is one of 2 that started in 2020, is one of 24 in phase 2, and was the 58th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

14 of the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with boserolimab (MK-5890), MK-4830, MK-0482 in participants with advanced squamous or non-squamous NSCLC that have been previously treated with anti-PD-L1 therapy.

This study is one of three pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).

Read the detailed description

The master screening protocol is MK-3475-U01 (KEYMAKER-U01) - NCT04165798

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • Programmed Cell Death Receptor 1 (PD-1, PD1)
  • Programmed Cell Death Receptor Ligand 1 (PD-L1, PDL1)
  • Programmed Cell Death Receptor Ligand 2 (PD-L2, PDL2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a - or cytologically-confirmed diagnosis of Stage IV squamous or non-squamous NSCLC.
  • Has non-squamous NSCLC and is not eligible for an approved targeted therapy.
  • Is able to provide sample collected either within 5 years or within the interval from completion of last treatment but before entering the screening period or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated obtained within 90 days of treatment initiation
  • Have progressed on treatment with an anti-PD-(L)1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other or other therapies
  • Have progressive disease (PD) during/after platinum doublet chemotherapy
  • Is able to complete all screening procedures within the 35-day screening window
  • Male participants must agree to use and refrain from donating sperm during the treatment period and for at least 120 days after the last dose of study treatment
  • Female participants must not be pregnant or breastfeeding, and at least one of the following conditions apply:

    1. Not a woman of (WOCBP) OR
    2. A WOCBP who agrees to use contraception during the treatment period and for at least 120 days after the last dose of study treatment
  • Has adequate organ function within 10 days of initiation of study treatment

Exclusion criteria

Exclusion Criteria:

  • Has a diagnosis of small cell lung cancer
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days before the first dose of study treatment
  • Has a known additional that is progressing or has required active treatment within the past 2 years
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis
  • Has an active disease that has required systemic treatment in the past 2 years
  • Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis
  • Has an active infection requiring systemic therapy
  • Has cardiac disease, including unstable angina, acute myocardial infarction within 6 months from Day 1 of study treatment, or Class III or IV congestive heart failure
  • Has a known history of (HIV) infection
  • Has a known history of or known active virus infection
  • Has known psychiatric or substance abuse disorders that would interfere with cooperating with the requirements of the study
  • Has had major surgery \<3 weeks before the first dose of study treatment
  • Has received prior radiation therapy to the lung that is >30 Gray (Gy) within 6 months of the first dose of study treatment
  • Has received a within 30 days before the first dose of study treatment. Any licensed COVID-19 vaccine (including for Emergency Use) in a particular country is allowed as long as they are messenger ribonucleic acid (mRNA) vaccines, adenoviral vaccines, or inactivated vaccines. vaccines (ie, those not licensed or approved for Emergency Use) are not allowed
  • Has received any prior immunotherapy and was discontinued from that treatment due to a severe or worse immune-related adverse event (irAE)
  • Has had chemotherapy or biological cancer therapy within 4 weeks before the first dose of study treatment or has not recovered to (CTCAE) Grade 1 or better from the AEs due to cancer therapeutics administered more than 4 weeks before the first dose of study treatment (including participants who had previous immunomodulatory therapy with residual irAEs)
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study treatment
  • Has participated in Substudies 1 or 2
  • Has had a severe reaction to treatment with monoclonal antibodies (including pembrolizumab) and/or any of their
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment
  • Has had an allogenic tissue/solid organ transplant
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Boserolimab

    On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS boserolimab IV for a maximum of 35 cycles (approximately 2 years). All participants are premedicated 1.5 hours (±30 minutes) before infusion of boserolimab with 50 mg oral (PO) diphenhydramine (or equivalent dose of antihistamine) and 500-1000 mg of acetaminophen PO (or equivalent dose of analgesic).

    Biological: Pembrolizumab · Biological: Boserolimab · Drug: diphenhydramine · Drug: acetaminophen

  • Experimental
    Pembrolizumab + MK-4830

    On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS MK-4830 IV for a maximum of 35 cycles (approximately 2 years).

    Biological: Pembrolizumab · Biological: MK-4830

  • Experimental
    Pembrolizumab + MK-0482

    On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS MK-0482 IV for a maximum of 35 cycles (approximately 2 years).

    Biological: Pembrolizumab · Biological: MK-0482

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by investigator.

    Time frame: Up to approximately 53 months

Secondary outcomes

  1. Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    PFS is defined as the time from first dose of study treatment until either the earliest date of documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by investigator per RECIST 1.1 is presented.

    Time frame: Up to approximately 53 months

  2. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.

    Time frame: Up to approximately 53 months

  3. Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.

    Time frame: Up to approximately 29 months

07

Results

Posted May 13, 2026

Participant flow

Participants were screened on the KEYMAKER-U01 master protocol and randomly assigned to a substudy arm in one of the multiple KEYMAKER substudies (U01A, U01B, or U01C) based on their eligibility. A total of 37 participants were randomized and treated in the Pembrolizumab + Boserolimab arm; 45 participants were randomized and treated in the Pembrolizumab + MK-4830 arm; and 45 participants were randomized and treated in the Pembrolizumab + MK-0482 arm.

Participant flow — Overall Study
MilestonePembrolizumab + BoserolimabPembrolizumab + MK-4830Pembrolizumab + MK-0482
Started374546
Treated374545
Completed000
Not completed374546
Withdrew: Sponsor decision154
Withdrew: Withdrawal by subject200
Withdrew: Death344041
Withdrew: Randomized in error001

Outcome measures

PrimaryObjective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by investigator.

Time frame:
Up to approximately 53 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Percentage of participantsPembrolizumab + BoserolimabPembrolizumab + MK-4830Pembrolizumab + MK-0482
Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)5.4 (0.7 to 18.2)11.1 (3.7 to 24.1)4.4 (0.5 to 15.1)
SecondaryProgression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

PFS is defined as the time from first dose of study treatment until either the earliest date of documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by investigator per RECIST 1.1 is presented.

Time frame:
Up to approximately 53 months
Reported as:
Median · Months
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
MonthsPembrolizumab + BoserolimabPembrolizumab + MK-4830Pembrolizumab + MK-0482
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)2.5 (1.4 to 2.9)2.4 (1.5 to 2.7)2.3 (1.4 to 4.7)
SecondaryNumber of Participants Who Experience One or More Adverse Events (AEs)

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.

Time frame:
Up to approximately 53 months
Reported as:
Number · Percentage of Participants
Number of Participants Who Experience One or More Adverse Events (AEs)
Percentage of ParticipantsPembrolizumab + BoserolimabPembrolizumab + MK-4830Pembrolizumab + MK-0482
Number of Participants Who Experience One or More Adverse Events (AEs)10093.391.1
SecondaryNumber of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.

Time frame:
Up to approximately 29 months
Reported as:
Number · Percentage of participants
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
Percentage of participantsPembrolizumab + BoserolimabPembrolizumab + MK-4830Pembrolizumab + MK-0482
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)16.217.86.7

Adverse events

Collected over Up to approximately 53 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab + Boserolimab36/37 (97.3%)14/37 (37.8%)34/37 (91.9%)
Pembrolizumab + MK-483040/45 (88.9%)17/45 (37.8%)39/45 (86.7%)
Pembrolizumab + MK-048241/46 (89.1%)14/45 (31.1%)34/45 (75.6%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventPembrolizumab + BoserolimabPembrolizumab + MK-4830Pembrolizumab + MK-0482
EncephalopathyNervous system disorders2/370/450/45
DyspnoeaRespiratory, thoracic and mediastinal disorders2/371/451/45
COVID-19Infections and infestations0/372/450/45
PneumoniaInfections and infestations1/372/452/45
DehydrationMetabolism and nutrition disorders0/370/452/45
HyponatraemiaMetabolism and nutrition disorders0/370/452/45
Pleural effusionRespiratory, thoracic and mediastinal disorders1/372/450/45
PneumothoraxRespiratory, thoracic and mediastinal disorders0/370/452/45
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/372/450/45
Adrenal insufficiencyEndocrine disorders1/371/450/45
Most frequent other events
Showing 10 of 40
Most frequent other events
EventPembrolizumab + BoserolimabPembrolizumab + MK-4830Pembrolizumab + MK-0482
FatigueGeneral disorders11/3710/458/45
PruritusSkin and subcutaneous tissue disorders11/376/458/45
CoughRespiratory, thoracic and mediastinal disorders8/379/4512/45
NauseaGastrointestinal disorders9/372/453/45
AnaemiaBlood and lymphatic system disorders6/378/454/45
DiarrhoeaGastrointestinal disorders6/376/453/45
Lymphocyte count decreasedInvestigations6/371/452/45
Decreased appetiteMetabolism and nutrition disorders6/374/456/45
DyspnoeaRespiratory, thoracic and mediastinal disorders6/374/455/45
ConstipationGastrointestinal disorders2/377/451/45

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pembrolizumab + BoserolimabPembrolizumab + MK-4830Pembrolizumab + MK-0482Total
Mean66.1 ± 9.065.6 ± 8.664.0 ± 9.365.2 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab + BoserolimabPembrolizumab + MK-4830Pembrolizumab + MK-0482Total
Female16272164
Male21182564
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab + BoserolimabPembrolizumab + MK-4830Pembrolizumab + MK-0482Total
Hispanic or Latino2002
Not Hispanic or Latino344546125
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab + BoserolimabPembrolizumab + MK-4830Pembrolizumab + MK-0482Total
American Indian or Alaska Native0000
Asian28111
Native Hawaiian or Other Pacific Islander0000
Black or African American2507
White333245110
More than one race0000
Unknown or Not Reported0000
08

Study locations

39 sites
  • Banner MD Anderson Cancer Center ( Site 0001)
    Gilbert, Arizona 85234, United States
  • City of Hope ( Site 0014)
    Duarte, California 91010, United States
  • UCSF Medical Center at Mission Bay ( Site 0007)
    San Francisco, California 94158, United States
  • Georgetown University ( Site 0036)
    Washington D.C., District of Columbia 20007, United States
  • University of Kentucky Markey Cancer Center ( Site 0019)
    Lexington, Kentucky 40536-0293, United States
  • MedStar Franklin Square Medical Center ( Site 0033)
    Baltimore, Maryland 21237, United States
  • Massachusetts General Hospital ( Site 0003)
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute ( Site 0002)
    Boston, Massachusetts 02215, United States
  • Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031)
    Omaha, Nebraska 68130, United States
  • Dartmouth Hitchcock Medical Center ( Site 0016)
    Lebanon, New Hampshire 03766, United States
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0037)
    Hackensack, New Jersey 07601, United States
  • Laura and Isaac Perlmutter Cancer Center ( Site 0034)
    New York, New York 10016, United States
  • Sanford Fargo Medical Center ( Site 0039)
    Fargo, North Dakota 58102, United States
  • Cleveland Clinic Main ( Site 0006)
    Cleveland, Ohio 44195, United States
  • Ohio State University Comprehensive Cancer Center ( Site 0015)
    Columbus, Ohio 43210, United States
  • Abramson Cancer Center of the University of Pennsylvania ( Site 0010)
    Philadelphia, Pennsylvania 19104, United States
  • Sanford Cancer Center ( Site 0038)
    Sioux Falls, South Dakota 57104, United States
  • The University of Texas MD Anderson Cancer Center ( Site 0009)
    Houston, Texas 77030, United States
  • Petz Aladar Megyei Oktato Korhaz ( Site 0062)
    Győr, Győr-Moson-Sopron 9024, Hungary
  • Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház ( Site 0061)
    Szolnok, Jász-Nagykun-Szolnok 5000, Hungary
  • Orszagos Koranyi Pulmonologiai Intezet ( Site 0060)
    Budapest, 1121, Hungary
  • Soroka Medical Center ( Site 0072)
    Beersheba, 8457108, Israel
  • Rambam Health Care Campus-Oncology ( Site 0076)
    Haifa, 3109601, Israel
  • Shaare Zedek Medical Center ( Site 0075)
    Jerusalem, 9103102, Israel
  • Meir Medical Center ( Site 0071)
    Kfar Saba, 4428132, Israel
  • Rabin Medical Center ( Site 0074)
    Petah Tikva, 4941492, Israel
  • Chaim Sheba Medical Center ( Site 0070)
    Ramat Gan, 5262000, Israel
  • Sourasky Medical Center ( Site 0077)
    Tel Aviv, 6423906, Israel
  • Azienda Ospedaliera Universitaria Careggi ( Site 0173)
    Florence, Firenze 50134, Italy
  • Policlinico Gemelli di Roma ( Site 0174)
    Rome, Lazio 00168, Italy
  • IRCCS Ospedale San Raffaele ( Site 0171)
    Milan, 20132, Italy
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier
    Warsaw, Masovian Voivodeship 02-781, Poland
  • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)
    Gdansk, Pomeranian Voivodeship 80-952, Poland
  • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0152)
    Koszalin, West Pomeranian Voivodeship 75-581, Poland
  • Seoul National University Bundang Hospital ( Site 0081)
    Seongnam-si, Kyonggi-do 13620, South Korea
  • Severance Hospital ( Site 0080)
    Seoul, 03722, South Korea
  • Samsung Medical Center ( Site 0082)
    Seoul, 06351, South Korea
  • ICO L Hospitalet ( Site 0090)
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Hospital Universitario Quiron Madrid ( Site 0091)
    Pozuelo de Alarcón, Madrid 28223, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Apr 2025, 63 months.

Results were first posted in May 2026, 1 year after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 63 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2019
First posted
Nov 15, 2019
StartActual
Jan 21, 2020
Primary completionActual
Apr 30, 2025
CompletionActual
May 28, 2025
Results first posted
May 13, 2026
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04165096
Responsible party
Sponsor
First posted
Nov 15, 2019
Start date
Jan 21, 2020
Primary completion
Apr 30, 2025
Completion
May 28, 2025
Results posted
May 13, 2026
Last update
Jun 26, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Boserolimab · Anti-ILT4 Monoclonal Antibody MK-4830 · Rolistobart

Start the discussion